Sept 23 (Reuters) - Zevra Therapeutics' ( ZVRA ) drug,

Miplyffa, for treating a rare and fatal genetic disorder will

have a wholesale acquisition cost ranging between $40,000 and

$106,000 per month depending on dosage, the company said on a

conference call on Monday.

The U.S. health regulator on Friday approved the drug making

it the first treatment to get a nod for Neimann-Pick disease

type C - a rare genetic condition that affects the nervous

system and other organs.